Clinical implications of discordance between low-density lipoprotein cholesterol and particle number

Otvos, 2002, Measurement issues related to lipoprotein heterogeneity, Am J Cardiol, 90, 22i, 10.1016/S0002-9149(02)02632-2

Cromwell, 2007, LDL particle number and risk for future cardiovascular disease in the Framingham Offspring Study—implications for LDL management, J Clin Lipidol, 1, 583, 10.1016/j.jacl.2007.10.001

Tabas, 2007, Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications, Circulation, 116, 1832, 10.1161/CIRCULATIONAHA.106.676890

Brunzell, 2008, Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation, J Am Coll Cardiol, 51, 1512, 10.1016/j.jacc.2008.02.034

Jeyarajah, 2006, Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy, Clin Lab Med, 26, 847, 10.1016/j.cll.2006.07.006

Rosenson, 2002, Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) Trial, Am J Cardiol, 90, 89, 10.1016/S0002-9149(02)02427-X

Mora, 2007, LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis, Atherosclerosis, 192, 211, 10.1016/j.atherosclerosis.2006.05.007

Kuller, 2002, Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the Cardiovascular Health Study, Arterioscler Thromb Vasc Biol, 22, 1175, 10.1161/01.ATV.0000022015.97341.3A

Mora, 2009, Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women, Circulation, 119, 931, 10.1161/CIRCULATIONAHA.108.816181

Otvos, 2006, LDL and HDL particle subclasses predict coronary events and are changed favorably by gemfibrozil therapy in the Veterans Affairs HDL Intervention Trial (VA-HIT), Circulation, 113, 1556, 10.1161/CIRCULATIONAHA.105.565135

El Harchaoui, 2007, Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study, J Am Coll Cardiol, 49, 547, 10.1016/j.jacc.2006.09.043

Glasziou, 2008, When should a new test become the current reference standard?, Ann Intern Med, 149, 816, 10.7326/0003-4819-149-11-200812020-00009

Bild, 2002, Multi-Ethnic Study of Atherosclerosis: objectives and design, Am J Epidemiol, 156, 871, 10.1093/aje/kwf113

Folsom, 2008, Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence, Arch Intern Med, 168, 1333, 10.1001/archinte.168.12.1333

O’Leary, 1996, Thickening of the carotid wall. A marker for atherosclerosis in the elderly? Cardiovascular Health Study Collaborative Research Group, Stroke, 27, 224, 10.1161/01.STR.27.2.224

Grundy, 2005, Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement, Circulation, 112, 2735, 10.1161/CIRCULATIONAHA.105.169404

Friedewald, 1972, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clin Chem, 18, 499, 10.1093/clinchem/18.6.499

Sniderman, 2008, Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice, J Clin Lipidol, 2, 36, 10.1016/j.jacl.2007.12.006

Sniderman, 2003, Concordance/discordance between plasma apolipoprotein B levels and cholesterol indexes of atherosclerotic risk, Am J Cardiol, 91, 1173, 10.1016/S0002-9149(03)00262-5

Berneis, 2002, Metabolic origins and clinical significance of LDL heterogeneity, J Lipid Res, 43, 1363, 10.1194/jlr.R200004-JLR200

2002, Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report, Circulation, 106, 3143, 10.1161/circ.106.25.3143

Kathiresan, 2006, Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study, Circulation, 113, 20, 10.1161/CIRCULATIONAHA.105.567107

Rosenson, 2009, Effects of rosuvastatin and atorvastatin on low-density and high-density lipoprotein particle concentrations in patients with the metabolic syndrome: a randomized, double-blind, controlled study, Diabetes Care, 32, 1087, 10.2337/dc08-1681

Cromwell, 2006, Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dL, Am J Cardiol, 98, 1599, 10.1016/j.amjcard.2006.07.036

Deedwania, 2006, Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study, Lancet, 368, 919, 10.1016/S0140-6736(06)69292-1

Hsia, 2008, Lipoprotein particle concentrations may explain the absence of coronary protection in the Women’s Health Initiative hormone trials, Arterioscler Thromb Vasc Biol, 28, 1666, 10.1161/ATVBAHA.108.170431

Kuvin, 2006, Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease, Am J Cardiol, 98, 743, 10.1016/j.amjcard.2006.04.011

Goldberg, 2005, A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with Type 2 diabetes and dyslipidemia, Diabetes Care, 18, 1547, 10.2337/diacare.28.7.1547

Kraus, 2002, Effects of the amount and intensity of exercise training on plasma lipoproteins, N Engl J Med, 347, 1483, 10.1056/NEJMoa020194